Naureen Quibria
Stock Analyst
(n/a)
# 4,648
Out of 4,648 analysts
13
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Top Industries:
Stocks Rated by Naureen Quibria
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMEA Biomea Fusion | Initiates: Overweight | $25 | $9.04 | +176.55% | 1 | Aug 29, 2024 | |
| IMMP Immutep | Initiates: Overweight | $10 | $1.82 | +449.45% | 1 | May 17, 2024 | |
| ERAS Erasca | Initiates: Overweight | $8 | $2.72 | +194.12% | 1 | Mar 11, 2024 | |
| CARM Carisma Therapeutics | Initiates: Overweight | $10 | $1.00 | +900.00% | 1 | Oct 3, 2023 | |
| IMCR Immunocore Holdings | Initiates: Overweight | $84 | $31.70 | +164.98% | 1 | Aug 16, 2023 | |
| ONCT Oncternal Therapeutics | Downgrades: Hold | n/a | $1.50 | - | 2 | Apr 4, 2023 | |
| DAWN Day One Biopharmaceuticals | Initiates: Overweight | $40 | $14.65 | +173.04% | 1 | Feb 8, 2023 | |
| FENC Fennec Pharmaceuticals | Initiates: Overweight | $11 | $4.34 | +153.46% | 1 | Sep 7, 2022 | |
| CMRX Chimerix | Initiates: Overweight | $7 | $0.99 | +607.07% | 2 | Sep 7, 2022 | |
| GNTA Genenta Science | Initiates: Buy | $21 | $5.45 | +285.32% | 1 | Jan 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $180 | $5.52 | +3,160.81% | 1 | Oct 14, 2021 |
Biomea Fusion
Aug 29, 2024
Initiates: Overweight
Price Target: $25
Current: $9.04
Upside: +176.55%
Immutep
May 17, 2024
Initiates: Overweight
Price Target: $10
Current: $1.82
Upside: +449.45%
Erasca
Mar 11, 2024
Initiates: Overweight
Price Target: $8
Current: $2.72
Upside: +194.12%
Carisma Therapeutics
Oct 3, 2023
Initiates: Overweight
Price Target: $10
Current: $1.00
Upside: +900.00%
Immunocore Holdings
Aug 16, 2023
Initiates: Overweight
Price Target: $84
Current: $31.70
Upside: +164.98%
Oncternal Therapeutics
Apr 4, 2023
Downgrades: Hold
Price Target: n/a
Current: $1.50
Upside: -
Day One Biopharmaceuticals
Feb 8, 2023
Initiates: Overweight
Price Target: $40
Current: $14.65
Upside: +173.04%
Fennec Pharmaceuticals
Sep 7, 2022
Initiates: Overweight
Price Target: $11
Current: $4.34
Upside: +153.46%
Chimerix
Sep 7, 2022
Initiates: Overweight
Price Target: $7
Current: $0.99
Upside: +607.07%
Genenta Science
Jan 13, 2022
Initiates: Buy
Price Target: $21
Current: $5.45
Upside: +285.32%
Oct 14, 2021
Initiates: Buy
Price Target: $180
Current: $5.52
Upside: +3,160.81%